OM Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

26.15M

-11.26%

-0.682

-87.7%

29.22M

-1.79%

-0.757

-76.65%

31.31M

-0.34%

-0.780

-7.14%

Estimates Revision

The market is revising Downward the revenue expectations for Outset Medical, Inc. (OM) for FY2025, with the revenue forecasts being adjusted by -5.86% over the past three months. During the same period, the stock price has changed by -70.28%.

Revenue Estimates for FY2025

Revise Downward

-5.86%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+3.6%

In Past 3 Month

Stock Price

Go Down

-70.28%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast OM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OM is 15.75 USD with a low forecast of 14.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

14.00

Averages

15.75

High

17.00

Current: 0.000

Low

14.00

Averages

15.75

High

17.00

RBC Capital

Shagun Singh

Sector Perform

downgrade

$17 -> $7

2025-12-17

Reason

RBC Capital

Shagun Singh

Price Target

$17 -> $7

2025-12-17

downgrade

Sector Perform

Reason

RBC Capital analyst Shagun Singh lowered the firm's price target on Outset Medical to $7 from $17 and keeps a Sector Perform rating on the shares as part of a broader research note previewing 2026 for Medical Supplies & Devices. The firm anticipates a year of positive momentum as sector fundamentals are solidly intact driven by the aging demographics, growing global healthcare access, and differentiated innovation, the analyst tells investors in a research note. For the company, RBC notes that Outset's Q3 miss and resulting downward revision in guidance was driven by delays in executing the company's commercial and sales transformation, as well as delays in closing several large deals that were originally anticipated in the second half of the year, and with execution misses in recent years, sentiment on the stock is "mixed at best".

BTIG

Marie Thibault

Buy

downgrade

$39 -> $17

2025-11-11

Reason

BTIG

Marie Thibault

Price Target

$39 -> $17

2025-11-11

downgrade

Buy

Reason

BTIG analyst Marie Thibault lowered the firm's price target on Outset Medical to $17 from $39 and keeps a Buy rating on the shares. The company's Q3 revenue of $29.4M fell short of the consensus estimate as Consumables revenue of $12.2M was below consensus of $14.7M, the analyst tells investors in a research note. The firm adds it is surprised by the shortfall as it viewed the guidance as relatively conservative following a strong Q2 print that included an uptick in Console revenue.

Stifel

Buy

downgrade

$17 -> $14

2025-11-11

Reason

Stifel

Price Target

$17 -> $14

2025-11-11

downgrade

Buy

Reason

Stifel lowered the firm's price target on Outset Medical to $14 from $17 and keeps a Buy rating on the shares. Softer-than-anticipated Consumable sales performance pushed total revenues below the firm's and consensus estimate, while the company highlighted their expectation for further delays in enterprise deal timing to continue and therefore lowered full-year guidance by about $7M at the midpoint, or more than the Q3 miss, the analyst tells investors. However, the "strong pipeline argues for better performance ahead," the analyst contends.

TD Cowen

Joshua Jennings

Buy

downgrade

$25 -> $15

2025-11-11

Reason

TD Cowen

Joshua Jennings

Price Target

$25 -> $15

2025-11-11

downgrade

Buy

Reason

TD Cowen analyst Joshua Jennings lowered the firm's price target on Outset Medical to $15 from $25 and keeps a Buy rating on the shares. The firm lower its target to reflect slightly slower-than-expected progress in the ongoing turnaround.

RBC Capital

Shagun Singh

Sector Perform

downgrade

$22 -> $17

2025-11-11

Reason

RBC Capital

Shagun Singh

Price Target

$22 -> $17

2025-11-11

downgrade

Sector Perform

Reason

RBC Capital analyst Shagun Singh lowered the firm's price target on Outset Medical to $17 from $22 and keeps a Sector Perform rating on the shares. The company delivered a 4% revenue miss and lowered 2025 guide by 5% due to delayed closing of several large deals forecasted for the second half of 2025 and potential impact from the Q4 departure of Head of Sales, the analyst tells investors in a research note. Outset Q4 guide implies accelerating sequential declines that may prove conservative however, the firm added.

BTIG

Marie Thibault

Buy

downgrade

$45 -> $37

2025-07-14

Reason

BTIG

Marie Thibault

Price Target

$45 -> $37

2025-07-14

downgrade

Buy

Reason

BTIG analyst Marie Thibault lowered the firm's price target on Outset Medical to $37 from $45 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results in MedTech. Healthcare was a laggard in Q2 relative to the S&P, and early into Q3, MedTech is underperforming as fears of Medicaid cuts and hospital closures weigh on the sector following recent legislation, the analyst tells investors in a research note. The fears are likely overblown, though the earnings season is likely to offer a mixed picture as sentiment is extremely binary right now, with some companies pushing extreme valuations and others "left for dead", BTIG notes. The firm adds however that on one hand, inflation is calm, markets are at highs, and Fx has turned demonstrably favorable.

Valuation Metrics

The current forward P/E ratio for Outset Medical Inc (OM.O) is -1.28, compared to its 5-year average forward P/E of -8.24. For a more detailed relative valuation and DCF analysis to assess Outset Medical Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.24

Current PE

-1.28

Overvalued PE

-1.25

Undervalued PE

-15.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7.46

Current EV/EBITDA

0.21

Overvalued EV/EBITDA

-1.18

Undervalued EV/EBITDA

-13.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

7.74

Current PS

0.56

Overvalued PS

15.26

Undervalued PS

0.22

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

OM News & Events

Events Timeline

No data

News

9.5

2025-12-30Globenewswire

Outset Medical Reports Q3 Earnings Miss, Stock Plummets 48.47%

8.5

2025-12-16Globenewswire

Osisko Metals Completes $32.48 Million Private Placement with Strategic Investors

8.5

2025-12-16Newsfilter

Osisko Metals Completes $32.48 Million Private Placement with Strategic Investors

People Also Watch

Frequently Asked Questions

What is Outset Medical Inc (OM) stock price today?

The current price of OM is 4.49 USD — it has decreased -3.85 % in the last trading day.

What is Outset Medical Inc (OM)'s business?

Outset Medical, Inc. is a medical technology company. It offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. It designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Tablo comprises various components, including Tablo Console, Tablo Cartridge, and Tablo Data Ecosystem. Tablo Console is a proprietary, compact, mobile and versatile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.

What is the price predicton of OM Stock?

What is Outset Medical Inc (OM)'s revenue for the last quarter?

Outset Medical Inc revenue for the last quarter amounts to 29.43M USD, increased 2.67 % YoY.

What is Outset Medical Inc (OM)'s earnings per share (EPS) for the last quarter?

Outset Medical Inc. EPS for the last quarter amounts to -1.00 USD, decreased -87.95 % YoY.

What changes have occurred in the market's expectations for Outset Medical Inc (OM)'s fundamentals?

How many employees does Outset Medical Inc (OM). have?

Outset Medical Inc (OM) has 354 emplpoyees as of January 09 2026.

What is Outset Medical Inc (OM) market cap?

Today OM has the market capitalization of 84.77M USD.